A t various times throughout its history, our nation was so threatened that groups not previously known to cooperate pulled together for a higher good-that of preserving the nation and the beliefs on which it is based. However, the road to mobilization of these groups was often long and circuitous. Typically, the risk of the nation being engulfed by a foreign power was slow to be acknowledged despite mounting evidence, until some catastrophic event illustrated the seriousness of the situation. Mobilization of the populace was invariably accompanied by slogans or songs that served to focus attention on the crisis at hand.
A different kind of crisis looms today: the American Health Care Crisis. Over the past 10 years, the intensity of our focus on the health care crisis has waxed and waned as other issues have entered the spotlight and then receded, but the crisis remains and, in fact, continues to grow. Put succinctly, our nation is torn between two seemingly oppos-ing forces-the desire to provide the quality and flexibility of health care that Americans demand and the need to control spiraling health care costs.
Various approaches to reconciling these opposing forces have been suggested. Most are aimed at reducing costs. As an example, the Health Care Financing Administration recently proposed a revision to conditions of participation in Medicare and Medicaid to remove the current regulatory requirement for a pharmacist to provide pharmaceutical services in hospitals.
This regulatory approach to the crisis is unlikely to achieve the desired outcomes of reducing costs and maintaining or improving the quality of health care. Any cost savings achieved are likely to be offset by higher costs in other areas and accompanied by reduced quality of care. The result, higher costs and reduced quality, will be the exact opposites of the intended outcomes.
A more rational approach would be a collaboration of each of the health care segments to achieve the desired outcomes. Without such collaboration, costs will rise and quality will suffer. Regulatory agencies, academia, industry, practitioners, and consumers must work together on a common goal. This, of course, may become difficult as politics and conflicting agendas begin to surface.
Although challenging, the collaborative approach can be successful. For example, pharmacists in Washington state have taken the lead in collaborating with various health care segments to develop prescriptive authority protocols. They have established a state-ofthe-art collaborative drug therapy program that allows pharmacists to participate in a broad range of therapeutic decision making. Working with the medical and nursing professions and with the State Board of Pharmacy, pharmacists can prescribe, under protocol, a wide variety of drugs. These programs reduce costs and increase qualitythe exact goals required in our troubled health care system.
A similar thought process led to the development of the Biotechnology Clerkship described in this issue of Hospital Pharmacy (p. 163). This clerkship is a collaborative effort of academia, industry, and practitioners. Its goal is to improve the quality of health care in Washington state. Such a program benefits each group in the collaborative effort, as well as others.
Academia benefits by having a pool of pharmacists who are qualified to teach biotechnology and perform biotechnology research. Moreover, by enhancing their relationship with the biotechnology industry, academia may have access to REDUCING PERFORMANCE-RELATED ERRORS Broad Causes of Medication Errors industry funds for support of biotechnology research and to experts who can enhance their educational course offerings. The biotechnology industry benefits by having a pool of individuals prepared to step into vacant positions. The biotechnology industry also has the opportunity to improve their return on investment through collaborative arrangements with other segments, such as academia.
Practitioners benefit by being better prepared to use biotechnology medicines and better able to defend their role should initiatives be introduced to remove them from the health care loop. State government benefits by having a pool of pharmacists qualified to offer a higher level of care to the populace and to fill vacant jobs in biotechnology. A qualified workforce also draws more industry into the state. Importantly, the patient benefits by receiving care from pharmacists who are trained to properly dispense biotechnology medicines and to instruct them in the use of these new products.
As the health care crisis continues, pharmacists in all segments of practice must form partnerships with their colleagues. Collaborative relationships at the local, state, and national levels are essential to improving health care systems. Lack of Knowledge outcomes should be enough by themselves to mobilize pharmacy professionals and other segments of the health care industry. But there is another incentive, too: If pharmacists don't mobilize, they may not be involved in the inevitable solutions to the health care crisis. So take heed: Band together to fight the coming battles, or risk losing your identity as central health care providers.
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